Adolfo De La Fuente Burguera

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.

Journal: Leukemia & lymphoma

Published: October 24, 2025

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 25, 2025

Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients.

Stellae-123 gene expression signature improved risk stratification in taiwanese acute myeloid leukemia patients.

Journal: Scientific reports

Published: January 27, 2024

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Journal: Frontiers in oncology

Published: September 27, 2023

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.

Journal: The Lancet. Haematology

Published: March 05, 2023

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.

Journal: Cancer medicine

Published: February 10, 2023

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Journal: Frontiers in oncology

Published: June 13, 2022

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

Journal: Blood cancer journal

Published: April 07, 2022

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.

Journal: Leukemia & lymphoma

Published: December 20, 2021

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.

Journal: Leukemia

Published: June 30, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026